The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kollnberger, S.
Right arrow Articles by Bowness, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kollnberger, S.
Right arrow Articles by Bowness, P.
The Journal of Immunology, 2004, 173: 1699-1710.
Copyright © 2004 by The American Association of Immunologists

HLA-B27 Heavy Chain Homodimers Are Expressed in HLA-B27 Transgenic Rodent Models of Spondyloarthritis and Are Ligands for Paired Ig-Like Receptors1

Simon Kollnberger*, Lucy A. Bird*, Matthew Roddis{dagger}, Cecile Hacquard-Bouder{ddagger}, Hiromi Kubagawa§, Helen C. Bodmer{dagger}, Maxime Breban{ddagger}, Andrew J. McMichael* and Paul Bowness2,*

* Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, United Kingdom; {dagger} The Edward Jenner Institute for Vaccine Research, Compton, United Kingdom; {ddagger} Cochin Hospital, Institut National de la Santé et de la Recherche Medicale, Centre National de la Recherche Scientifique, Université René Descartes, Paris, France; and § Division of Developmental and Clinical Immunology, University of Alabama, Birmingham, AL 35294


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
HLA-B27 transgenic rats and strains of HLA-B27-transgenic {beta}2-microglobulin ({beta}2m)-deficient mice develop a multisystem inflammatory disease affecting the joints, skin, and bowel with strong similarity to human spondyloarthritis. We show that HLA-B27 transgenic mice and rats express HC10-reactive, {beta}2m-free HLA-B27 homodimers (B272) and multimers, both intracellularly and at the cell surface of leukocytes, including rat dendritic cells. Fluorescent-labeled tetrameric complexes of HLA-B27 homodimers (B272 tetramers) bind to populations of lymphocytes, monocytes, and dendritic cells. The murine (and probably rat) paired Ig-like receptors (PIRs) are ligands for B272. Thus, B272 tetramers stain RBL cells transfected with murine activating PIR-A4 and inhibitory PIR-B receptors. Murine PIR-A and -B can be immunoprecipitated from the RAW264.7 macrophage cell line, and murine PIR-A can be immunoprecipitated from the J774.A1 line using B272. B272 tetramer staining corresponds to the distribution of PIR expression on lymphoid and myeloid cells and on murine macrophage cell lines. B272 can induce TNF-{alpha} release from the J774.A1 macrophage cell line. The binding of B272 to PIR is inhibited by HC10, an mAb that ameliorates arthritis in HLA-B27+ {beta}2m–/– mice. The expression and PIR recognition of B272 could explain the pathogenesis of rodent spondyloarthritis.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The human MHC class I allele, HLA-B27, confers susceptibility to a group of closely related arthritic diseases collectively referred to as spondyloarthropathies (reviewed in Ref.1). The most striking association is observed for ankylosing spondylitis, where >94% of patients express HLA-B27 compared with ~9% of normal controls (2). The pathogenesis of these diseases remains obscure, and the basis for the association with HLA-B27 has not been established.

Animal models of spondyloarthropathy have confirmed the contribution of HLA-B27 to disease pathogenesis. Two transgenic rat lines, 33-3 and 21-4H, carrying high gene copy numbers of HLA-B27 and its human {beta}2-microglobulin ({beta}2m)3 partner, consistently develop multiorgan inflammation, resembling human HLA-B27-associated disease (3). Disease features include colitis, enteritis, peripheral and axial arthritis, male genital inflammation, and psoriform skin and nail lesions (3). By contrast, other rat lines (21-4L and 25-6), bearing fewer copies of the transgenes, do not develop disease. HLA-B7 transgenic rats are healthy, and HLA-Cw6 transgenic rats exhibit only transient diarrhea and forepaw swelling (4). Disease can be transferred to HLA-B27 transgenic or nontransgenic rats by transplantation of bone marrow or fetal liver cells from high expressing rat lines (5). Previous studies suggested a role for T cells, with CD4+ cells being more efficient than CD8+ in transferring disease (6). However, recent work has implicated a population of CD8+ monocytes whose numbers are expanded in disease and reduced after ameliorative therapy with an anti-CD8 mAb (7). Disease expression is also dependent on the presence of bacterial flora (8).

Most mice transgenic for HLA-B27 remain healthy, but can develop arthritis and nail changes if the mouse {beta}2m gene is either deleted or replaced with the human homologue (HLA-B27+ {beta}2m–/–, HLA-B27+ {beta}2m–/– h{beta}2m+) (9, 10). Symptoms, including arthritis and nail changes, develop on transfer from a specific pathogen-free environment to conventional conditions (9). Although {beta}2m-associated HLA-B27 is not expressed in HLA-B27+ {beta}2m–/– mice, {beta}2m-free HLA-B27 H chains could be detected on the surface of thymic epithelium and Con A-treated lymphoid cells (9, 10). Furthermore, disease development was delayed by treatment with the H chain-specific mAb HC-10 (10). By contrast, an mAb with specificity for {beta}2m-associated HLA-B27 (ME-1) failed to modulate disease (10). This led to the proposal that the expression of free HLA-B27 H chains on the cell surface is involved in the development of spontaneous inflammatory disease in HLA-B27 transgenic mice lacking {beta}2m (10). By contrast, neither murine MHC class II molecules (11) nor TAP-1 (12) were required.

Recently, we have shown that HLA-B27 can form H chain homodimers (B272) in vitro, disulfide-bonded through residue cysteine 67, which are not associated with {beta}2m (13). Furthermore, we have shown that B272 are expressed on the surface of human lymphoid cell lines (13, 14) and in HLA-B27-positive patients with spondyloarthritis (15).

In this study we show firstly that HLA-B27-transgenic animals express HC10-reactive HLA-B27 H chains as homodimers and multimers in a variety of lymphoid cells, both intracellularly and at the cell surface. Secondly, tetrameric complexes of HLA-B27 homodimers (B272 tetramers) bind to populations of myeloid and B cells. The murine (and probably rat) paired Ig-like receptors (PIRs) are ligands for B272, and HC10 mAb inhibits the PIR/B272 interaction.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Transgenic animals and cell lines

HLA-B*2705/human {beta}2m homozygous transgenic mice, obtained from E. Weiss (Institute for Anthropology and Human Genetics, Ludwig Maximilians Universität München, Munich, Germany) (16), were backcrossed onto C57BL/6 to ensure an H2b background. They were then bred with {beta}2m knockout mice (The Jackson Laboratory, Bar Harbor, ME). Mice were bred and maintained at the Edward Jenner Institute of Vaccine Research (Compton, U.K.). Con A-activated blasts were generated from freshly isolated murine splenocytes by culture in DMEM (Invitrogen Life Technologies, Gaithersburg, MD) supplemented with 10% FCS (Invitrogen Life Technologies), 2 mM glutamine, 50 U/ml penicillin, 50 U/ml streptomycin, 50 µM 2-ME, and 20 mM HEPES in six-well plates (2 x 107 cells/well) for 40 h in 8 ml of RPMI 1640 supplemented with FCS, glutamine, HEPES, 2-ME, and Con A (Sigma-Aldrich, St. Louis, MO) to 2.5 µg/ml.

The transgenic rat lines used in this study were bred and maintained at the Cochin Hospital (Paris, France) have been previously described (3) (17) and are detailed in Table I. Rat dendritic cells (DC) were isolated from freshly harvested spleens from transgenic and control rats splenocytes by metrizamide separation after overnight culture as described previously (18) (19).


View this table:
[in this window]
[in a new window]
 
Table I. Transgenic rat lines used in this studya

 
The murine macrophage cell lines, M1, J774.A1, and RAW264.7, were obtained from the European Collection of Cell Cultures. The PIR-A4- and PIR-B-transfected RBL-2H3 cell lines (20) and the LBL721.220 cell line transfected with HLA-B*2705 or HLA-B7 (21) have been described previously.

Cell lysis and Western blot analysis

Cell lysis (5 x 106 cells/sample) was conducted in 500 µl of lysis buffer (20 mM Tris (pH 8.0), 150 mM NaCl, 1% Triton X-100, 10 mM iodoacetamide (IAA), and 2 mM PMSF) on ice for 30 min. We have previously shown that postlysis dimerization of HLA-B27 H chains does not occur under these conditions (14). Nuclei and cell debris were pelleted (13,000 rpm 10 min at 4°C). Twenty microliters of lysate was boiled (3 min) in SDS sample buffer (50 mM Tris-HCl, 2% SDS, 10% (v/v) glycerol, and bromophenol blue) with or without the reducing agent DTT (100 mM) and was run on a 10% SDS-PAGE gel. Proteins were transferred onto nitrocellulose membranes (Hybond-C Super; Amersham Biosciences, Piscataway, NJ) using a SemiPhor Unit (Amersham Biosciences). The membranes were blocked overnight at 4°C in blocking buffer (PBS containing 5% (w/v) milk powder (Marvel; Nestlé UK, Croydon, U.K.), and 0.1% Tween 20 (Sigma-Aldrich)). HLA-B27 H chains were detected by incubation with the H chain-specific mAb HC-10 (22) and diluted in blocking buffer, for 1 h at room temperature, followed by washes with blocking buffer, incubation with peroxidase-conjugated goat anti-mouse Ig (Dakocytomation, Carpenteria, CA) and ECL reagent (Amersham Biosciences), and exposure to film (Biomax MR-1; Eastman Kodak, Rochester, NY).

Cell surface labeling and immunoprecipitation

Rat and mouse splenocytes or lymph node cells and DC were surface-labeled using either lactoperoxidase-catalyzed iodination (23) or biotinylation. Briefly, 1–2 x 107 cells/condition were pelleted and washed twice in ice-cold Dulbecco’s PBS. Radioiodination was conducted at room temperature for 15–20 min in 500 µl of iodination buffer (PBS containing 10 µl of lactoperoxidase, 0.2 U/ml glucose oxidase, 5 mM {beta}-D-glucose, and 500 µCi of iodine 125) with gentle agitation every 5 min. Unincorporated 125I was removed with washes in PBS/5 mM potassium iodide. Biotinylation of cell surface proteins was performed using EZ-Link Sulfo-NHS-LC-Biotin (Pierce, Rockford, IL). Cell surface proteins were biotinylated by incubating 2 x 107 cells/ml with 0.5 mg/ml EZ-Link Sulfo-NHS-LC-Biotin (Pierce) in PBS at room temperature for 15 min. Cells were then washed once with RPMI 1640 and twice with ice-cold PBS, then lysed for immunoprecipitation. Freshly prepared IAA (10 mM) was included in all steps from cell lysis and in some experiments (e.g., that shown in Fig. 1C) cells were pretreated with IAA for 15 min before biotinylation/iodination. Cell lysates were cleared with rotation at 4°C with 80 µl of protein A-Sepharose beads (10%, v/v; Sigma-Aldrich) for 1 h (14). H chains were then immunoprecipitated with 10 µg/ml HC10 for 1 h, followed by protein A-Sepharose beads (60 µl) for an additional 1 h (4°C). Beads were washed three times with lysis buffer, and a final wash with 10 mM Tris was performed; mAb-Ag complexes were eluted from the beads by boiling (5 min) in SDS-PAGE sample buffer, and supernatants (10–20 µl) were analyzed on 10% SDS-PAGE gels. Gels were fixed in 10% methanol/10% acetic acid and dried down on 3MM paper (Whatman, Clifton, NJ) before autoradiography on Kodak X-OMAT film. Biotinylated blots were developed using streptavidin HRP and ECL reagent (Amersham Biosciences).



View larger version (26K):
[in this window]
[in a new window]
 
FIGURE 1. HLA-B27 forms homodimers in HLA-B27 transgenic {beta}2m-deficient murine splenocytes. HLA-B27 homodimers and multimers are expressed on the surface of Con A-activated transgenic mouse splenocytes. A, Cell lysates from transgenic and nontransgenic littermates were resolved by nonreducing (upper panel) and reducing (lower panel) SDS-PAGE, followed by HC-10 Western blot. Arrowheads indicate the positions of B272 dimers (90 kDa) and monomers (45 kDa). B, Con A-activated mouse splenocytes were surface-iodinated before immunoprecipitation of human H chains with HC10. Complexes were resolved by SDS-PAGE. Note that HC-10 also precipitates a non-B27 band in nontransgenic cells, which reduces to ~50 kDa. C, HC10-reactive cell surface H chain dimers and multimers are detected by biotinylation. Cells were pretreated with and all stages were performed in the presence of 10 mM iodoacetamide. The ~80-kDa band on the reduced gel is not HC10-reactive on Western blot (data not shown).

 
Generation of B272 tetramers

HLA-B*2705 was expressed and refolded as described previously (13, 15). B272 tetramers were generated in which each HLA-B27 homodimer carried only a single biotin tag, by refolding a mixture of B27-biotin and B27 histidine-tagged proteins in the presence of one of the following known viral peptide epitopes: KRWIIMGLNK (HIV gag), or RRIYDLIEL (EBV EBNA3C). Refolded protein was biotinylated and then purified on Ni-NTA resin (Fast-flow; Amersham Biosciences). Composition was confirmed by nonreducing and reducing SDS-PAGE. PE-labeled ExtrAvidin (Sigma-Aldrich) was then used to generate tetramer complexes.

Standard B27/{beta}2m complexes were refolded with {beta}2m and the peptides listed above or with SRYWAIRTR (influenza nucleoprotein 383–391) as previously described (13, 15). Control HLA-A2/{beta}2m/flu peptide, HLA-A24 or HLA-B8, or B*702/{beta}2m/HIV tetramers were generated under identical conditions as previously described (13, 15). The extracellular domains of HLA-B*702 and B8, expressed under identical conditions and refolded in the same buffer for the same time (48 h) in the presence of cognate peptide, but not {beta}2m, did not form homodimers (S. Kollnberger, A. J. McMichael, and P. Bowness, manuscript in preparation). They did form H chain aggregates, which eluted at the same volume on fast protein liquid chromatography as HLA-B27 aggregates relative to molecular mass standards (corresponding to an Mr of 160,000–250,000). The presence of H chains in these aggregates was verified by analysis by reducing SDS-PAGE. Subsequently, aggregates were biotinylated under identical conditions and used as a control for FACS staining. For the experiment shown in Fig. 4E, biotinylated B272 bound to streptavidin beads was used to immunoprecipitate RAW264.7 lysates (after preclearing with unconjugated streptavidin beads and beads conjugated with HLA-A2/{beta}2m/peptide complexes) or J774.A1 lysates (with control immunoprecipitates in parallel). Proteins pulled down by B272 were subsequently resolved by SDS-PAGE and blotted as described above. Blots were developed with the rat anti-PIR mAbs 6C1 or 10.1 (24) (H. Kubagawa, unpublished observations) and HRP-conjugated goat anti-rat Ig (Dakocytomation).



View larger version (24K):
[in this window]
[in a new window]
 
FIGURE 4. B272 bind to murine PIR-A and -B receptors. A, B272 tetramer binding to murine B lymphocytes and monocytes correlates with PIR expression. BALB/c splenocytes were preincubated with Fc block and then incubated on ice with B272 PE-tetramer or anti-PIR mAb (6C1) and anti-CD19-allophycocyanin. Plots were gated on live lymphocytes. B, B272 PE-tetramers stain PIR-expressing murine macrophage cell lines. Monocyte/macrophage cell lines M1, RAW364.7, and J774.A1 were stained with B272 PE-tetramer or control tetramers (ExtrAvidin-PE, HLA-A2/{beta}2m/CMV, or HLA-B8/{beta}2m/HIV nef; upper panels) or with the anti-PIRa/B mAb 6C1 (lower panels). C, HC10 inhibits B272 binding to J774.A1 cells. D, B272 tetramers bind PIR-A and PIR-B transfected RBL cells. RBL and RBL-PIR transfectants were stained with ExtrAvidin-PE, B272 PE-tetramer, HLA-B27/{beta}2m/HIV peptide PE-tetramer, A2/{beta}2m/flu peptide PE-tetramer, B7, B8, and B27 H chain aggregate tetramers, and anti-PIR (6C1) and anti-rat IgG-FITC (MFI of FL2 shown). E, B272-coated beads im-munoprecipitate PIR from the RAW264.7 and J774.A1 monocytic cell lines. Left panel, RAW364.7 cell lysates were precleared with unconjugated streptavidin beads and HLA-A2/{beta}2m/CMV-coated beads, then immunoprecipitated with B272-coated beads. Proteins were eluted from beads and resolved by 12% SDS-PAGE. Membranes were blotted with anti-PIR (6C1) and anti-rat Ig-HRP, then exposed to film. The band at ~22 kDa represents nonspecific staining at the bottom of the gel. Right panel, J774.A1 lysate was immunoprecipitated with streptavidin beads (lane 1), HLA-B27/{beta}2m/nucleoprotein beads (lane 2), and then B272-coated beads (lane 3) before SDS-PAGE and Western blot with rat anti-PIR (10.1) and anti-rat Ig-HRP.

 


View larger version (31K):
[in this window]
[in a new window]
 
FIGURE 4D. Continued

 
Stimulation of J774.A1 cells with biotinylated B272

Twenty-four-well tissue culture plates (Nunc, Naperville, IL) were coated with 0.25 ml of ExtrAvidin (40 µg/ml) in Dulbecco’s PBS, pH 7.4 (endotoxin-free; Sigma-Aldrich), overnight at 4°C. Wells were washed four times with PBS and then blocked with 10% FCS/PBS for 1 h at room temperature. Wells were washed, and 5 µg of biotinylated protein, biotinylated anti-PIRA/B (6C1), or rat IgG1 isotype control mAb (BD Pharmingen, San Diego, CA) was added for 1 h at room temperature. After washing, 0.5 x 106 J774.A1 cells or control M1 cells in RPMI 1640 medium with 10% FCS were added. Polymixin B sulfate (10 µg/ml; Sigma-Aldrich) was used to block LPS-mediated effects. Supernatants were harvested after 24 h for determination of TNF-{alpha} levels using the murine/rat TNF-{alpha} ELISA kit (BD Pharmingen) or nitrite levels using Griess reagent (Promega, Madison, WI). Blocking experiments were performed in the presence of 10 µg/ml HC10 or IgG2a isotype control mAb.

FACS staining

Cells (5 x 105 to 1 x 106) were stained on ice with 1–10 µg/ml mAb for 30 min in the presence of azide. In some experiments FcRs were preblocked with 10% normal mouse or rat serum (Sigma-Aldrich) and rat anti-mouse CD16/32-specific mAb 2.4G2 or mouse anti-rat CD32-specific mAb D34-485 (BD Pharmingen). After washing in PBS, 1 mg/ml BSA, and 0.05% sodium azide at 4°C, tetramer staining was conducted at 4°C for 30 min or 37°C for 15 min using 1 µg of tetramer/106 cells in the presence of azide. Cells were resuspended in PBA or were fixed in 2% paraformaldehyde before cytometric analysis on a FACSCalibur using CellQuest software (BD Biosciences, Mountain View, CA). For HC10 blocking experiments, tetramer or cells were preincubated with HC10 mAb or isotype control Ab for 15 min at 4°C before staining as described above.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
HLA-B27+ {beta}2m–/– murine splenocytes express HLA-B27 homodimers and multimers

Given that soluble recombinant HLA-B27 H chains can form {beta}2m-free homodimers disulfide-bonded through Cys67 (13), we tested whether they can also dimerize in mouse splenocytes lacking endogenous {beta}2m. Western blot with the mAb HC10, which is specific for free human class I H chains, showed that almost all HLA-B27 H chains are present as dimers with a molecular mass of ~90 kDa (Fig. 1A, upper panel, lane 3). Lane 4 shows that dimers were also present in splenocytes transgenic for HLA-B27 and human {beta}2m (HLA-B27+, h{beta}2m+, m{beta}2m–/–), although a 45-kDa band, almost certainly representing monomeric HLA-B27 H chains associated with h{beta}2m, was more abundant. In the presence of DTT, all dimers in the HLA-B27+ {beta}2m–/– mice were reduced to a single 45-kDa monomer band (Fig. 1A, lower panel). The two or three bands seen at ~90 kDa under nonreducing conditions probably represent differently disulfide-bonded homodimers. Additional faint, low molecular mass bands were seen after DTT treatment of the HLA-B27+ h{beta}2m+ splenocytes, probably representing degradation of HLA-B27 H chains, as observed previously (25).

Con A-stimulated HLA-B27-transgenic {beta}2m–/– mouse splenocytes express low levels of surface HC10 reactivity (9, 10). To determine whether this HC10 staining could be partly due to cell surface B272 expression, Con A-activated splenocytes were surface-labeled with either 125I (Fig. 1B) or biotin (Fig. 1C), and lysates were immunoprecipitated with HC10. Experiments were performed in the presence of IAA to prevent artifactual dimerization. Fig. 1B shows that cell surface HC10-reactive material was composed of HLA-B27 H chain monomers, dimers, and multimers. The right panel shows that these dimers and multimers largely reduced to a 45-kDa band in the presence of DTT. No significant difference in the level of surface HLA-B27 H chain expression, as detected by HC10, was observed between HLA-B27 transgenic and HLA-B27+ h{beta}2m+ double-transgenic splenocytes. Surface biotinylation, shown in Fig. 1C, confirmed the presence of HLA-B27 dimer and also higher molecular mass bands. The HC10 Western blot confirmed the presence of HLA-B27 H chains in the dimer band reducing to 45-kDa monomers and showed that the ~80-kDa band seen on the reduced gel was not HLA-B27 (data not shown).

In HLA-B27 transgenic rats, splenocytes, lymph node cells, and DC express HLA-B27 H chains in homodimeric and multimeric forms

We next studied lysates from lymph node and spleen mononuclear cells from the HLA-B27 transgenic and nontransgenic rat lines shown in Table I. Cells from the diseased 33-3 HLA-B27 rat with a high copy number of the HLA-B27 transgene showed high expression levels of B272 (Fig. 2A, lane 4). Three prominent B272 bands of ~90 kDa were resolved. B272 accounted for ~50% of the total H chains by densitometry (data not shown). Their levels were lower in 21-4L rats with fewer copies of HLA-B27 and were lower still (<10% total H chains) in rats transgenic for HLA-B7, which lacks Cys67. Almost all dimers were thiol-labile and reduced to a single 45-kDa band in the presence of DTT (Fig. 2A, right panels).



View larger version (27K):
[in this window]
[in a new window]
 
FIGURE 2. HLA-B27 homodimers and multimers are expressed in lymph nodes and spleen and on the surface of DC from HLA-B27 transgenic rats. A, Cell lysates from B27 transgenic (12 and 55 copies), B7 transgenic (52 copies), and nontransgenic littermates were resolved by nonreducing (left panel) and reducing (right panel) SDS-PAGE, followed by HC-10 Western blot. Arrowheads indicate the positions of dimers and monomers. Rat lymph node cells are shown in the upper panels, and splenocytes are shown in the lower panels. B, HC-10 immunoprecipitation of surface-iodinated DC. Complexes were then resolved by nonreducing and reducing SDS-PAGE. Note that cells were not preincubated with Con A. An unidentified band of <25 kDa was also seen at the dye front at the bottom of the gel.

 
We next looked for cell surface B272 on the surface of rat DC by radioiodination, followed by HC10 immunoprecipitation. HC10-reactive HLA-B27 H chain monomers, dimers, and multimers were present on DC (Fig. 2B). Thus, a population of professional rat APCs expressed significant levels of cell surface B272 and multimers, consistent with previous evidence implicating bone marrow- and fetal liver-derived cells in disease (5). Interestingly, in some experiments low levels of homodimers could also be detected on the surface of HLA-B7 transgenic rat DC (Fig. 2B, right panel, third lane). Because the tapasin-deficient human B cell line LBL721.220 transfected with HLA-B*2705 expresses high levels of surface B272 and multimers (14), we studied LBL721.220 transfected with HLA-B7 instead. Homodimers of HLA-B7 were not detected at the cell surface (data not shown). Furthermore, recombinant HLA-B7 molecules refolded in vitro did not form homodimers (S. Kollnberger, unpublished observations). These results suggest that there are significant differences in the cell biology of HLA class I homodimer expression between rat and human APC and that HLA-B27 is unusual in surviving so well without {beta}2m.

Tetrameric complexes of HLA-B27 H chain homodimers stain populations of murine B cells and monocytes

To test whether B272 bind to murine cells, fluorescent B272 tetramers were generated. Fig. 3, A and C, shows that B272 tetramers consistently stained 1–10% of splenocytes within the lymphocyte gate. These were CD3 negative (Fig. 3A), CD19 positive (Fig. 3, B and C) B lymphocytes; their frequencies did not differ significantly between HLA-B27 transgenic and nontransgenic mice. These cells scarcely bound standard HLA-B27 and HLA-A2 tetramers above levels observed with ExtrAvidin-PE. Binding of the B272 tetramers to B lymphocytes could be blocked by HC10 mAb, but not by IgG2a isotype control mAb (Fig. 3C).



View larger version (58K):
[in this window]
[in a new window]
 
FIGURE 3. B272 tetramers stain murine CD19+ B cells and CD11b+ monocytes. Staining is inhibited by the HC10 mAb. A and B, HLA-B27+ m{beta}2m–/– (B27 Tg) and C57BL/6 m{beta}2m–/– (non-Tg) mouse splenocytes were stained with B272 PE-tetramers or controls (extravidin-PE, HLA-B27/{beta}2m/gag peptide PE-tetramer, and HLA-A2/{beta}2m/flu peptide PE-tetramer). In addition, cells were stained with anti-CD3-FITC (A) or anti-CD19-FITC (B). C, Splenocytes from a healthy BALB/c mouse were double-stained with B272 PE-tetramers and anti-CD19-FITC after preincubation of tetramer with HC10 or isotype control Ab. D, HLA-B27+ m{beta}2m–/– (HLA-B27 Tg) and C57BL/6 m{beta}2m–/[minus] (non-Tg) mouse splenocytes were stained with B272 PE-tetramers or controls (extravidin-PE, HLA-B27/{beta}2m/gag peptide PE-tetramer, and HLA-A2/{beta}2m/flu peptide PE-tetramers) together with anti-CD11b-FITC. E, Splenocytes from a healthy BALB/c mouse were double-stained with B272 PE-tetramers and anti-CD16/32-FITC after preincubation of tetramer with HC10 or isotype control Ab. A–C, Plots were gated on live lymphocytes; D and E, Plots were gated on myelomonocytic cells. Numbers indicate the percentage of gated cells in quadrant.

 


View larger version (69K):
[in this window]
[in a new window]
 
FIGURE 3D. Continued

 
Fig. 3, D and E, show that B272 tetramers also strongly stain murine monocytes, including most CD11b- and CD16-positive cells within the myelomonocytic gate. This was consistently observed in both HLA-B27 transgenic animals and nontransgenic animals of different strains. Some nonspecific background staining of both monocytes and B cells with ExtrAvidin-PE was observed, which was higher for cells stained at 37°C than at 4°C (data not shown). Fig. 3E shows that B272 staining could be blocked with HC10, but not with IgG2a isotype control mAb.

B272 tetramers bind murine PIRs; binding is inhibited by HC10 mAb

We noted that the same mouse and rat cell populations that bind B272 tetramers also express PIRs (e.g., murine B, myeloid, and DC lineages, but not T or NK cells) (24, 26). In repeated experiments similar numbers of murine B lymphocytes and monocytes were stained with B272 tetramer and with the PIR-specific 6C1 mAb (Fig. 4A). 6C1 is a nonblocking mAb that binds both PIR-A and PIR-B (24). This correlation extended to murine monocyte/macrophage cell lines expressing PIRs (Fig. 4B). Thus, homodimer tetramers failed to bind to the monocytic cell line M1 that showed the weakest PIR expression. B272 tetramer staining of the J774.A1 cell line was inhibited with the HC10 mAb (Fig. 4C).

We next studied RBL-2H3 cells transfected with murine PIR-A4 or PIR-B. Fig. 4D shows that B272 tetramers specifically bind to PIR-expressing transfectants; moreover, staining correlated with the level of PIR expression. By contrast, neither control HLA-A2 or HLA-B27 heterodimers tetramers nor PE-conjugated B*0702 and B8 H chain aggregate bound to the RBL-PIR transfectants. PE-conjugated HLA-B27 H chain aggregates stained PIRA4-transfected RBL-2H3 cells (Fig. 4D, second experiment). Weaker staining of RBL-PIRB transfectants was also observed (data not shown). The B272 tetramer staining could be partially inhibited by preincubating the tetramers with the HC10 mAb or by preincubating the cells with a 10-fold excess of unlabeled B272 monomer (data not shown).

We next used B272-coated beads to immunoprecipitate lysates from the RAW264.7 and J774.A1 monocytic cell lines. Proteins were eluted from beads, resolved by 12% SDS-PAGE, and subjected to Western blot with the rat anti-PIR mAbs 6C1 or 10.1. Fig. 4E (left panel) shows that B272 clearly immunoprecipitates two PIR-reactive bands of ~85 and 120 kDa, corresponding to PIR-A and -B, respectively. The band around 22 kDa represents material at the dye front. Fig. 4E (right panel) shows that B272 (but not heterodimeric complexes) immunoprecipitates PIR-A from J774.A1 cells.

B272 tetramers, but not HLA-A2 or HLA-B27 heterodimer tetramers, stain populations of rat B cells, CD4+ CD8+ monocytes, and DC

We next used B272 tetramers to stain splenocytes and lymph nodes from healthy and transgenic rat strains. B272 tetramers did not stain rat T lymphocytes (Fig. 5A, left panel), but stained 2–8% of B cells (Fig. 5A, right panel). B272 tetramers bound B cells from HLA-B27 transgenic, HLA-B7 transgenic, and nontransgenic rats (data not shown).



View larger version (31K):
[in this window]
[in a new window]
 
FIGURE 5. B272 tetramers stain rat B cells and monocytes. A, B272 tetramers stain rat B, but not T, cells. Healthy PVG rat splenocytes were double-stained with B272 PE-tetramers and anti-{alpha}{beta}TCR-FITC (left panel) or anti-rat Ig-FITC (B cell marker; right panel). Plots were gated on live lymphocytes. B, B272 tetramer staining of rat monocytes. Splenocytes from a healthy PVG rat were four-color stained with mAbs to CD4 (OX35)-Cy5, CD8 (OX8)-PerCP, CD172a, CD161a, or CD11b/c, together with HC-B27 PE-tetramer or ExtrAvidin-PE control tetramers. Cells in density plot A were gated to include small lymphocytes and larger lymphoblastoid cells, denoted G1, as shown in density plot B. Region d was gated for small lymphocytes (G2). C, Splenocytes from an HLA-B27hi diseased rat, a healthy nontransgenic rat, and B7-transgenic control rats were stained with mAbs to CD4 (OX35)-Cy5 and CD8 (OX8)-PerCP (and CD161a; data not shown) as in B together with B272 PE-tetramer or control tetramers (ExtrAvidin-PE, HLA-A2/{beta}2m/flu peptide or HLA-B8/{beta}2m/HIV peptide PE-tetramer). Histogram plots were gated on CD4+ CD8+ cells as in B, sequence b. D, B272 tetramer staining of DC from HLA-B27 transgenic rats. Staining was conducted at 4°C after preblocking with normal rat serum and anti-CD32.

 
Recently, May and colleagues (7) have identified a population of CD4+ CD8+ myelomonocytic cells expressing CD11b/c, CD172a and CD161a (NKR-P1A) that is expanded in HLA-B27 transgenic rats with inflammatory disease. Interestingly, nearly all the cells in this same subset bound B272 tetramers (Fig. 5B, region b). As shown in Fig. 5A, we detected binding to none of the T cells (regions a and c) and to 2–5% of B cells (region d). We next looked for differences in B272 tetramer staining of splenocytes from HLA-B27 transgenic diseased rats and nontransgenic and HLA-B7 transgenic controls. Fig. 5C shows that tetramer staining of CD4+ CD8+ CD161+ macrophages was observed in all rat strains, and that ExtrAvidin-PE and control tetrameric complexes did not stain this cell population. Lastly, we asked whether rat DC carry receptors for B272. B272 tetramers (but not heterodimeric HLA-A2 tetramers) bound to purified DC from both HLA-B27 transgenic rats (Fig. 5D) and B7 and nontransgenic controls (data not shown). Binding was blocked by HC10, but not by isotype control mAb.

B272 induces TNF {alpha} release from J774.A1 cells

Fig. 6 shows a representative experiment in which B272 complexes immobilized on streptavidin-coated plates specifically induced TNF-{alpha} release by the J774.A1 macrophage cell line. ExtrAvidin alone or standard HLA-A2 heterodimeric complexes gave only a low/background level of TNF production (Fig. 6A). Production of TNF-{alpha} by J774.A1 cells could also be stimulated by cross-linking FcRs in the presence of IFN-{gamma}. Similar results were obtained when B272 complexes were preincubated with cells before addition of extravidin (data not shown). All experiments were set up and performed in the presence of 10 µg/ml polymyxin B sulfate, which abrogated LPS-induced TNF production (see Fig. 6C), but had no significant effect on B272-induced TNF production (data not shown). The lower panel of Fig. 6A shows that plate-bound anti-PIRA/B mAb (6C1), but not isotype control rat IgG1, also induced TNF-{alpha} secretion by J774.A1 cells. Fig. 6B shows that B272 also induced nitrite release from J774.A1 cells. Nitrite release was increased in the presence of the cross-linking anti-FcR Ab 2.4G2; this release was inhibited by HC10, but not by an isotype IgG2a mAb. Fig. 6C shows that B272 complexes did not induce TNF-{alpha} from the M1 cell line, which expresses little PIR and does not stain significantly with B272 (see Fig. 4B).



View larger version (13K):
[in this window]
[in a new window]
 
FIGURE 6. Stimulation of J774.A1 cells with plate-bound B272 protein. Five micrograms of biotinylated B272, control protein, biotinylated anti-PIRA/B (6C1), or isotype control mAb (rat IgG1) was added to ExtrAvidin-coated wells for 1 h at room temperature. J774 cells (0.5 x 106; A and B) or M1 cells (0.5 x 106; C) were then added. Polymixin B sulfate was used to block LPS-mediated effects. Supernatants were harvested after 24 h for measurement of TNF-{alpha} by ELISA or of nitrite using Griess reagent.

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
In this paper we describe the expression of HLA-B27 H chain dimers (B272) and multimers in transgenic rodent models of disease. Receptors for B272 are expressed on B cells and cells of the monocyte/macrophage lineage. The latter include a population of CD4+ CD8+ rat monocytes that have been recently implicated in disease pathogenesis (7). We show that the murine activatory PIR-A and inhibitory PIR-B receptors bind B272, and it is likely that PIRs are the principal B272 receptor in vivo, because the distribution of B272 receptor expression correlates with PIR expression for both the mouse and the rat. HC10, an mAb that ameliorates arthritis in HLA-B27+ {beta}2m–/– mice (10), inhibits the B272/PIR interaction.

HLA-B27-transgenic mice and rats express B27 homodimers and multimers

HLA-B27 H chain expression has been previously detected with the HC10 mAb in HLA-B27+ m{beta}2m–/– mice (9, 10). We show that a substantial proportion of these H chains are expressed as {beta}2m-free homodimers and multimers, both intracellularly and on the surface of murine splenocytes and rat DC. We propose that these molecules have a role in disease pathogenesis, either through intracellular expression of B272 and induction of a proinflammatory stress response (27) or, more likely, though cell surface recognition by the immune system. Intracellular B272, resolved by SDS-PAGE under nonreducing conditions, show three bands at ~90 kDa. This molecular mass heterogeneity is also seen in HLA-B27-transfected human cell lines, where cysteine mutagenesis suggests that differing intra- or intermolecular disulphide bond pairing is responsible (14). Two-dimensional isoelectric focusing under reducing and nonreducing conditions confirms the presence of B272 (data not shown) (14, 15). We have previously shown in cell mixing experiments that B27 dimer formation does not occur postlysis under the conditions used in this study (15). The HC10mAb also immunoprecipitated surface-biotinylated HLA-B27 H chains after IAA pretreatment (Fig. 1C), making it unlikely that cell surface dimers are an artifact of the iodination process. The additional band(s) seen on HC10 IP of surface-labeled material would be consistent with the presence of additional molecules, such as ERp57 (25) or BIP (GRP78) (28), disulphide-bonded to HLA-B27 H chains.

H chain homodimer formation has also been observed previously for certain murine alleles, apparently via their unpaired cytoplasmic Cys (23). This could also explain the low levels of a single 90-kDa band seen in this study for HLA-B7, which lacks the unpaired Cys67 in the {alpha}1 helix (14). Homodimerization (and homotrimerization) through unpaired cysteine residues has also recently been described for the nonclassical HLA-G (29). We propose that HLA-B27 homodimerization stabilized by Cys67 could lead to a unique homodimer conformation. This is supported by our data showing that cell surface expression of B272 in human cells is dependent on the unpaired Cys67 (14). It is also possible that the higher molecular mass multimeric forms of HLA-B27 may play a significant functional role in vivo.

Studies with murine MHC class I molecules have suggested that H chain dimer formation is related to the availability of {beta}2m (23). In its absence, dimers form in the ER and can traffic to the cell surface in murine cells (as confirmed in this study, shown in Fig. 1B); in its presence, they can form in a post-Golgi compartment after {beta}2m dissociation from unstable complexes. The recent finding that on certain backgrounds disease can occur in {beta}2m–/– mice without any need for the HLA-B27 transgene (28) suggests that dimerization of some mouse alleles might contribute to spondyloarthropathy, and that {beta}2m could be protective. Indeed, it is possible that murine free H chains or H chain dimers are the natural ligands for PIRs (see below).

The dependence on high HLA-B27 copy number for rat disease (17) is also consistent with a role for excess H chains and suggests a quantitative effect, perhaps through saturation of peptide supply or other Ag presentation machinery. Notably under certain conditions other alleles can be induced to form homodimers in vivo (28).

Murine PIRS bind B272: rat PIR expression could account for the distribution of homodimer receptors

We have shown that B272 bind to cells of the monocyte/macrophage lineage and to a subset of B cells from HLA-B27-transgenic and nontransgenic rodents of different strains. B272 tetramer staining of murine cells ex vivo correlates with PIR expression on B cells and monocytes, but not T or NK cells (24). B272 tetramers stained PIR-transfected RBL cells and PIR-expressing macrophage cell lines. Moreover, PIR-A and -B could be immunoprecipitated from macrophage cell lines by B272, but not HLA-A2 or HLA-B27 heterodimers. It is possible that some of the other homodimeric or H chain structures besides B272 may bind receptors such as PIRs. We have attempted to control for this by generating PE-conjugated B*0702 and B8 H chain aggregate. These did not bind to PIR-A transfected cells. By contrast, PE-conjugated H chain aggregates of HLA-B27 were able to bind PIR transfectants. Binding of B272 to PIRs could be inhibited with the HC10 mAb, which has previously been reported to ameliorate disease in HLA-B27-transgenic {beta}2m knockout mice (10). B272 complexes induced TNF and nitrite production by the PIR-expressing murine macrophage line J774.A1.

In the mouse there are at least six Pira genes, encoding (putative) activatory PIR-A receptors with short cytoplasmic tails and a charged arginine residue in their transmembrane domain that facilitates association with adaptor proteins such as the FcR common {gamma}-chain to form a cell activation complex (30). PIR-B is encoded by a single Pirb gene (31) and contains four potential ITIM motifs in the cytoplasmic tail (32). We show that both the murine activatory PIR-A4 and the inhibitory PIR-B are ligands for B272.

The rodent PIRs share considerable sequence homology (40–60%) with the human leukocyte Ig-like receptor (LILR)/leukocyte Ig receptor (LIR) family of receptors (26). We have also shown that standard heterodimeric complexes of HLA-B27, -B8, or -A2 with {beta}2m and antigenic peptides are not ligands for murine PIRs. Although the murine ligands for PIRs remain to be elucidated, it has recently been shown that the human MHC class Ib molecule HLA-G can bind to the murine PIR-B (33). Binding of HLA-G tetramers to bone marrow-derived DCs induced phosphorylation of PIR-B receptors and inhibited cellular maturation. In keeping with this observation, HLA-G transgenic mice have compromised maturation of functional DCs (33), as do HLA-B27 transgenic rats (19). Taken together these results raise the possibility that PIRs might be receptors for murine free class 1 H chains or for nonclassical MHC molecules. It is possible that interaction of B272 with one of the activating PIR-A isoforms may drive inflammation through enhanced cytokine production (as shown in this study for TNF-{alpha}). To this end it may be significant that rat B-lymphocytes express only activating PIR-A receptors. In contrast myelomonocytic cells express PIR-B as well as PIR-A, and it is possible that interaction of B272 with PIR may inhibit or modulate immune function. Notably PIR-B–/– mice show impaired DC maturation and increased Th2 responses (34). Interestingly, LPS results in significant up-regulation of PIR expression on B cells and macrophages (24), suggesting one possible explanation for the necessity of bacterial flora for disease generation (8, 9).

Although our results suggest a model in which B272 expressed by APC interact with PIRs on monocytes or B cells to induce or perpetuate immunopathology, our findings do not exclude a role for NK cells (which in the rat can express the inhibitory PIR-B (26)) or T lymphocytes through either indirect mechanisms or induction of PIR expression under distinct conditions. It is also important to point out that B272-reactive NK family receptors can be expressed by human NK and T cells (see below), and that rodent receptors with sequence homology to human NK receptors have recently been identified (35).

Rat DC express B272, B27 multimers, and receptors for B272

We have shown that splenic DCs from HLA-B27 transgenic rats with inflammatory disease express significant levels of cell surface B27 homodimers and multimers. Previous cell transfer experiments have shown that transplantation of bone marrow or fetal liver cells from high expressing HLA-B27 transgenic rats can elicit disease in both transgenic and nontransgenic recipients (5). It is, therefore, possible that the expression of B272 by bone marrow-derived DCs is involved in disease pathogenesis. We have also shown that rat DC express receptors for B272. These are likely to be PIR; rat myeloid cells express both PIR-A and -B. Coexpression of both B272 and B272 ligand could have significant functional implications and might explain the impaired DC function described in HLA-B27 transgenic rats (19).

Implications for human spondyloarthritis

Patients with ankylosing spondylitis express B272 on mononuclear cells (15) and show increased levels of HC10 staining on monocytes (36). Moreover, there are receptors for B272 in these patients (15). The observations in humans and rodents are consistent with a role for the interaction of B272 with immunoreceptors in inflammatory disease. Crucial to this hypothesis, we have shown firstly that B272 receptors are present in rodent models of disease, and secondly that B272 binds a different set of immunoreceptors to normally conformed HLA-B27/{beta}2m/peptide molecules in both rodents and humans. Thus, B272 tetramers bind to the human immunoreceptors LILRB2 (also known as LIR2 or ILT4), (37), LILRA1 (37), killer Ig-related receptor 3DL1 (KIR3DL1) (37), and KIR3DL2 (15), but not to LILRB1 (LIR1 or ILT2) (37). In contrast, HLA-B27/{beta}2m/peptide complexes do not bind to PIRs significantly and bind human LIR1, but not KIR3DL2 (37) (15). There are, however, species differences in the cellular expression pattern of B272 receptors between humans and rodents. Whereas B272 tetramers did not stain murine or rat CD3+ T lymphocytes, we have observed binding to up to 6% of human T cells (in addition to B cell and monocyte staining), consistent with binding to three domain KIR receptors (15).

Evidence for a key role of TNF-{alpha} in spondyloarthritis

We have shown that B272 can induce TNF-{alpha} release from macrophages in vitro. TNF-{alpha} expression has been demonstrated within the inflamed sacroiliac joints of patients with ankylosing spondylitis (38), where macrophages and T cells are demonstrable (39). Furthermore, recent therapeutic trials with anti-TNF-{alpha} blockers in human disease have shown striking clinical benefit (40, 41) and radiological resolution of inflammation on magnetic resonance image scanning (42). Such benefits have not been reported with T cell-targeted therapies.

Although our data suggest a pathogenic role for cell surface B272 through interaction with immunoreceptors, other mechanisms may be involved. Mear and colleagues (27) have suggested that intracellular expression of B272 may induce a proinflammatory stress response. We have shown that B272 are abundantly expressed intracellularly in rodent disease models and could indeed set up an unfolded protein stress response. Our data are also compatible with models in which B272/PIR interactions might costimulate the generation of peptide-specific T cell responses, commensurate with data suggesting a role for CD4+ T cells in rat disease (6) and the finding of CD4 and CD8 T cell responses to triggering bacteria in human reactive spondyloarthritis (43, 44, 45).

In conclusion, our data show that HLA-B27 H chains are expressed as dimers and multimers in transgenic rodent models of spondyloarthritis. We also show that both mice and rats express receptors for B272 on B cells and cells of the monocyte/macrophage lineage. PIRs are the principal B272 receptor in mice and probably also in rats. We provide evidence that B272 can have a functional effect on murine macrophages. These findings suggest that the interaction of B272 with immunoreceptors on cells of the myelomonocytic lineage or on B lymphocytes might be involved in the pathogenesis of spondyloarthritis.


    Acknowledgments
 
We are grateful to Dr. N. Willcox for critical reading of the manuscript, to Dr. K. de Gleria for peptide synthesis/technical assistance and to Drs. I. Hermans and G. Brown for reagents.


    Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by the Medical Research Council of the United Kingdom and the Arthritis Research Campaign. Back

2 Address correspondence and reprint requests to Dr. Paul Bowness, Medical Research Council Human Immunology Unit, University of Oxford, Oxford, U.K. OX3 9DS. E-mail address: pbowness{at}gwmail.jr2.ox.ac.uk Back

3 Abbreviations used in this paper; {beta}2m, {beta}2-microglobulin; B272, HLA-B27 H chain homodimer; DC, dendritic cell; h, human; IAA, iodoacetamide; KIR, killer Ig-related receptor; LILR, leukocyte Ig-like receptor; LIR, leukocyte Ig receptor; PIR, paired Ig-like receptor. Back

Received for publication November 3, 2003. Accepted for publication May 17, 2004.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Allen, R. L., P. Bowness, A. McMichael. 1999. The role of HLA-B27 in spondyloarthritis. Immunogenetics 50:220.[Medline]
  2. Brown, M. A., K. D. Pile, L. G. Kennedy, A. Calin, C. Darke, J. Bell, B. P. Wordsworth, F. Cornelis. 1996. HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom. Ann. Rheum. Dis. 55:268.[Abstract/Free Full Text]
  3. Hammer, R. E., S. D. Maika, J. A. Richardson, J.-P. Tang, J. D. Taurog. 1990. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human {beta}2m: an animal model of HLA-B27-associated human disorders. Cell 63:1099.[Medline]
  4. Taurog, J. D., S. D. Maika, N. Satumtira, M. L. Dorris, I. L. McLean, H. Yanagisawa, A. Sayad, A. J. Stagg, G. M. Fox, A. Le O’Brien, et al 1999. Inflammatory disease in HLA-B27 transgenic rats. Immunol. Rev. 169:209.[Medline]
  5. Breban, M., R. E. Hammer, J. A. Ricardson, J. D. Taurog. 1993. Transfer of the inflammatory disease of HLA-B27 transgenic rats by bone marrow engraftment. J. Exp. Med. 178:1607.[Abstract/Free Full Text]
  6. Breban, M., S. J. Fernandez, J. A. Richardson, R. R. Hadavand, S. D. Maika, R. E. Hammer, J. D. Taurog. 1996. T cells, but not thymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats. J. Immunol. 156:794.[Abstract]
  7. May, E., M. L. Dorris, N. Satumtira, I. Iqbal, M. I. Rehman, E. Lightfoot, J. D. Taurog. 2003. CD8{alpha}{beta} T cells are not essential to the pathogenesis of arthritis or colitis in HLA-B27 transgenic rats. J. Immunol. 170:1099.[Abstract/Free Full Text]
  8. Taurog, J. D., J. A. Richardson, J. T. Croft, W. A. Simmons, M. Zhou, S. J. L. Fernandez, E. Balish, R. E. Hammer. 1994. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J. Exp. Med. 180:2359.[Abstract/Free Full Text]
  9. Khare, S. D., H. S. Luthra, C. S. David. 1995. Spontaneous inflammatory arthritis in HLA-B27 transgenic mice lacking {beta}2-microglobulin: a model of human spondyloarthropathies. J. Exp. Med. 182:1153.[Abstract/Free Full Text]
  10. Khare, S. D., J. Hansen, H. S. Luthra, C. S. David. 1996. HLA-B27 heavy chains contribute to spontaneous inflammatory disease in B27/human {beta}2-microglobulin ({beta}2m) double transgenic mice with disrupted mouse {beta}2m. J. Clin. Invest. 98:2746.[Medline]
  11. Khare, S. D., M. J. Bull, J. Hanson, H. S. Luthra, C. S. David. 1998. Spontaneous inflammatory disease in HLA-B27 transgenic mice is independent of MHC class II molecules: a direct role for B27 heavy chains and not B27-derived peptides. J. Immunol. 160:101.[Abstract/Free Full Text]
  12. Khare, S. D., S. Lee, M. J. Bull, J. Hanson, H. S. Luthra, C. S. David. 2001. Spontaneous inflammatory disease in HLA-B27 transgenic mice does not require transporter of antigenic peptides. Clin. Immunol. 98:364.[Medline]
  13. Allen, R. L., C. A. O’Callaghan, A. J. McMichael, P. Bowness. 1999. Cutting edge: HLA-B27 can form a novel {beta}2-microglobulin-free heavy chain homodimer structure. J. Immunol. 162:5045.[Abstract/Free Full Text]
  14. Bird, L. A., C. A. Peh, S. Kollnberger, T. Elliott, A. J. McMichael, P. Bowness. 2003. Lymphoblastoid cells express HLA-B27 homodimers both intracellularly and at the cell surface following endosomal recycling. Eur. J. Immunol. 33:748.[Medline]
  15. Kollnberger, S., L. Bird, M. Y. Sun, C. Retiere, V. M. Braud, A. McMichael, P. Bowness. 2002. Cell-surface expression and immune receptor recognition of HLA-B27 homodimers. Arthritis Rheum. 46:2972.[Medline]
  16. Weiss, E. H., G. Schliesser, C. Botteron, A. McMichael, G. Riethmuller, F. Kievits, P. Ivanyi, G. Brem. 1990. HLA class-I-transgenic mice as model system to study MHC-restricted antigen recognition in man. Scand. J. Rheumatol. 87:(Suppl.):91.
  17. Taurog, J. D., S. D. Maika, W. A. Simmons, M. Breban, R. E. Hammer. 1993. Susceptibility to inflammatory disease in HLA-B27 transgenic rat lines correlates with the level of B27 expression. J. Immunol. 150:4168.[Abstract]
  18. Knight, S. C., J. Mertin, A. Stackpoole, J. Clark. 1983. Induction of immune responses in vivo with small numbers of veiled (dendritic) cells. Proc. Natl. Acad. Sci. USA 80:6032.[Abstract/Free Full Text]
  19. Stagg, A. J., M. Breban, R. E. Hammer, S. C. Knight, J. D. Taurog. 1995. Defective dendritic cell (DC) function in a HLA-B27 transgenic rat model of spondyloarthropathy (SpA). Adv. Exp. Med. Biol. 378:557.[Medline]
  20. Uehara, T., M. Blery, D. W. Kang, C. C. Chen, L. H. Ho, G. L. Gartland, F. T. Liu, E. Vivier, M. D. Cooper, H. Kubagawa. 2001. Inhibition of IgE-mediated mast cell activation by the paired Ig-like receptor PIR-B. J. Clin. Invest. 108:1041.[Medline]
  21. Peh, C. A., S. R. Burrows, M. Barnden, R. Khanna, P. Cresswell, D. J. Moss, J. McCluskey. 1998. HLA-B27-restricted antigen presentation in the absence of tapasin reveals polymorphism in mechanisms of HLA class I peptide loading. Immunity 8:531.[Medline]
  22. Stam, N. J., H. Spits, H. L. Ploegh. 1986. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J. Immunol. 137:2299.[Abstract]
  23. Capps, G. G., B. E. Robinson, K. D. Lewis, M. C. Zuniga. 1993. In vivo dimeric association of class I MHC heavy chains: possible relationship to class I MHC heavy chain-{beta}2-microglobulin dissociation. J. Immunol. 151:159.[Abstract]
  24. Kubagawa, H., C. C. Chen, L. H. Ho, T. S. Shimada, L. Gartland, C. Mashburn, T. Uehara, J. V. Ravetch, M. D. Cooper. 1999. Biochemical nature and cellular distribution of the paired immunoglobulin-like receptors, PIR-A and PIR-B. J. Exp. Med. 189:309.[Abstract/Free Full Text]
  25. Antoniou, A. N., S. Ford, M. Alphey, A. Osborne, T. Elliott, S. J. Powis. 2002. The oxidoreductase ERp57 efficiently reduces partially folded in preference to fully folded MHC class I molecules. EMBO J. 21:2655.[Medline]
  26. Dennis, G., Jr, R. P. Stephan, H. Kubagawa, M. D. Cooper. 1999. Characterization of paired Ig-like receptors in rats. J. Immunol. 163:6371.[Abstract/Free Full Text]
  27. Mear, J. P., K. L. Schreiber, C. Munz, X. Zhu, S. Stevanovic, H. G. Rammensee, S. L. Rowland-Jones, R. A. Colbert. 1999. Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies. J. Immunol. 163:6665.[Abstract/Free Full Text]
  28. Kingsbury, D. J., J. P. Mear, D. P. Witte, J. D. Taurog, D. C. Roopenian, R. A. Colbert. 2000. Development of spontaneous arthritis in {beta}2-microglobulin-deficient mice without expression of HLA-B27: association with deficiency of endogenous major histocompatibility complex class I expression. Arthritis Rheum. 43:2290.[Medline]
  29. Gonen-Gross, T., H. Achdout, R. Gazit, J. Hanna, S. Mizrahi, G. Markel, D. Goldman-Wohl, S. Yagel, V. Horejsi, O. Levy, et al 2003. Complexes of HLA-G protein on the cell surface are important for leukocyte Ig-like receptor-1 function. J. Immunol. 171:1343.[Abstract/Free Full Text]
  30. Maeda, A., M. Kurosaki, T. Kurosaki. 1998. Paired immunoglobulin-like receptor (PIR)-A is involved in activating mast cells through its association with Fc receptor {gamma} chain. J. Exp. Med. 188:991.[Abstract/Free Full Text]
  31. Kubagawa, H., P.D. Burrows, M.D. Cooper. 1997. A novel pair of immunoglobulin-like receptors expressed by B cells and myeloid cells. Proc. Natl. Acad. Sci. USA 94:5261.[Abstract/Free Full Text]
  32. Blery, M., H. Kubagawa, C. C. Chen, F. Vely, M. D. Cooper, E. Vivier. 1998. The paired Ig-like receptor PIR-B is an inhibitory receptor that recruits the protein-tyrosine phosphatase SHP-1. Proc. Natl. Acad. Sci. USA 95:2446.[Abstract/Free Full Text]
  33. Liang, S., B. Baibakov, A. Horuzsko. 2002. HLA-G inhibits the functions of murine dendritic cells via the PIR-B immune inhibitory receptor. Eur. J. Immunol. 32:2418.[Medline]
  34. Ujike, A., K. Takeda, A. Nakamura, S. Ebihara, K. Akiyama, T. Takai. 2002. Impaired dendritic cell maturation and increased TH2 responses in PIR-B–/– mice. Nat. Immunol. 3:542.[Medline]
  35. Hoelsbrekken, S. E., O. Nylenna, P. C. Saether, I. O. Slettedal, J. C. Ryan, S. Fossum, E. Dissen. 2003. Cutting edge: molecular cloning of a killer cell Ig-like receptor in the mouse and rat. J. Immunol. 170:2259.[Abstract/Free Full Text]
  36. Tsai, W. C., C. J. Chen, J. H. Yen, T. T. Ou, J. J. Tsai, C. S. Liu, H. W. Liu. 2002. Free HLA class I heavy chain-carrying monocytes: a potential role in the pathogenesis of spondyloarthropathies. J. Rheumatol. 29:966.[Abstract/Free Full Text]
  37. Allen, R. L., T. Raine, A. Haude, J. Trowsdale, M. J. Wilson. 2001. Leukocyte receptor complex-encoded immunomodulatory receptors show differing specificity for alternative HLA-B27 structures. J. Immunol. 167:5543.[Abstract/Free Full Text]
  38. Braun, J., M. Bollow, L. Neure, E. Seipelt, F. Seyrekbasan, H. Herbst, U. Eggens, A. Distler, J. Sieper. 1995. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 38:499.[Medline]
  39. Bollow, M., T. Fischer, H. Reisshauer, M. Backhaus, J. Sieper, B. Hamm, J. Braun. 2000. Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis: cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann. Rheum. Dis. 59:135.[Abstract/Free Full Text]
  40. Braun, J., J. Brandt, J. Listing, A. Zink, R. Alten, W. Golder, E. Gromnica-Ihle, H. Kellner, A. Krause, M. Schneider, et al 2002. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359:1187.[Medline]
  41. Gorman, J. D., K. E. Sack, J. C. Davis, Jr. 2002. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor {alpha}. N. Engl. J. Med. 346:1349.[Abstract/Free Full Text]
  42. Braun, J., X. Baraliakos, W. Golder, J. Brandt, M. Rudwaleit, J. Listing, M. Bollow, J. Sieper, D. Van Der Heijde. 2003. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum. 48:1126.[Medline]
  43. Hermann, E., D. T. Yu, Z. B. K. Meyer, B. Fleischer. 1993. HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet 342:646.[Medline]
  44. Viner, N. J., L. C. Bailey, P. F. Life, P. A. Bacon, J. S. H. Gaston. 1991. Isolation of Yersinia specific T cell clones from the synovial membrane and synovial fluid of a patient with reactive arthritis. Arthritis Rheum. 34:1151.[Medline]
  45. Kuon, W., H. G. Holzhutter, H. Appel, M. Grolms, S. Kollnberger, A. Traeder, P. Henklein, E. Weiss, A. Thiel, R. Lauster, et al 2001. Identification of HLA-B27-restricted peptides from the Chlamydia trachomatis proteome with possible relevance to HLA-B27-associated diseases. J. Immunol. 167:4738.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
S. Endo, Y. Sakamoto, E. Kobayashi, A. Nakamura, and T. Takai
Regulation of cytotoxic T lymphocyte triggering by PIR-B on dendritic cells
PNAS, September 23, 2008; 105(38): 14515 - 14520.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
A. Masuda, A. Nakamura, T. Maeda, Y. Sakamoto, and T. Takai
Cis binding between inhibitory receptors and MHC class I can regulate mast cell activation
J. Exp. Med., April 16, 2007; 204(4): 907 - 920.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. Shiroishi, K. Kuroki, L. Rasubala, K. Tsumoto, I. Kumagai, E. Kurimoto, K. Kato, D. Kohda, and K. Maenaka
Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d)
PNAS, October 31, 2006; 103(44): 16412 - 16417.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. J. Turner, D. P. Sowders, M. L. DeLay, R. Mohapatra, S. Bai, J. A. Smith, J. R. Brandewie, J. D. Taurog, and R. A. Colbert
HLA-B27 Misfolding in Transgenic Rats Is Associated with Activation of the Unfolded Protein Response
J. Immunol., August 15, 2005; 175(4): 2438 - 2448.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kollnberger, S.
Right arrow Articles by Bowness, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kollnberger, S.
Right arrow Articles by Bowness, P.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS